オプションチェーンは、Hoth Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Hoth Therapeuticsの市場センチメントを評価します。.

Hoth Therapeutics (NASDAQ:HOTH) 株価情報, オプションチェーン

Hoth Therapeutics

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

Hoth Therapeutics Inc

PTPI

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

WIIM

SCI stock has given up its prior gain. Service Corp International shares were trading higher after the company reported better-than-expected Q1 financial results and issued FY25 adjusted EPS guidance with its midpoint above estimates.

OMF stock has given up its prior loss. OneMain Holdings shares were trading lower on possible continued weakness after the company reported a Q1 sales miss on Tuesday.

Comfort Systems USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIX#NYSE">FIX</a>) has outperformed the market over the past 15 years by 15.6% on an annualized basis producing an average annual return of 26.79%. Currently, Comfort Systems USA has a market capitalization of $14.02 billion. 
Buying $100 In FIX: If an investor had bought $100 of FIX stock 15 years ago, it would be worth $3,285.54 today based on a price of $397.55 for FIX at the time of writing.
<h3>Comfort Systems USA's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746054013_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<a href="https://www.cnbc.com/2025/04/30/court-finds-apple-executive-lied-under-oath.html" title="https://www.cnbc.com/2025/04/30/court-finds-apple-executive-lied-under-oath.html">https://www.cnbc.com/2025/04/30/court-finds-apple-executive-lied-under-oath.html</a>

Legal

AAPL

'Court Finds Apple, Executive Lied Under Oath In Epic Games Trial' - CNBC

Barclays analyst Trevor Young maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Equal-Weight and lowers the price target from $55 to $53.

Price Target

Analyst Ratings

ETSY

Barclays Maintains Equal-Weight on Etsy, Lowers Price Target to $53

Barclays analyst Brandon Oglenski maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Overweight and lowers the price target from $135 to $125.

Barclays Maintains Overweight on XPO, Lowers Price Target to $125

Barclays analyst George Wang maintains Garmin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) with a Underweight and lowers the price target from $188 to $152.

GRMN

Barclays Maintains Underweight on Garmin, Lowers Price Target to $152

RB Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBA#NYSE">RBA</a>) has outperformed the market over the past 10 years by 4.43% on an annualized basis producing an average annual return of 14.68%. Currently, RB Global has a market capitalization of $18.63 billion. 
Buying $100 In RBA: If an investor had bought $100 of RBA stock 10 years ago, it would be worth $392.29 today based on a price of $100.66 for RBA at the time of writing.
<h3>RB Global's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746053111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In RB Global 10 Years Ago Would Be Worth This Much Today

Barclays analyst Tim Long maintains Zebra Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) with a Equal-Weight and lowers the price target from $326 to $263.

ZBRA

Barclays Maintains Equal-Weight on Zebra Technologies, Lowers Price Target to $263

Barclays analyst Andrew Mok maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight and raises the price target from $161 to $171.

Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $171

Barclays analyst Saket Kalia maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Equal-Weight and lowers the price target from $40 to $33.

TENB

Barclays Maintains Equal-Weight on Tenable Holdings, Lowers Price Target to $33

Barclays analyst Jeffrey Bernstein maintains Sysco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>) with a Overweight and lowers the price target from $87 to $77.

Barclays Maintains Overweight on Sysco, Lowers Price Target to $77

Samsung Electronics Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) reported <a href="https://www.benzinga.com/topic/samsung" target="_blank" rel="noreferrer noopener">first-quarter revenue</a> growth of 10% year-on-year to 79.1 trillion Korean won ($55.5 billion) Wednesday.
Revenue growth marked an all-time quarterly high, driven by strong sales of flagship Galaxy S25 smartphones and <a target="_blank" href="https://www.samsung.com/global/ir/" rel="noreferrer noopener">high-value-added products</a>.
Operating profit was 6.7 trillion Korean won ($17.62 billion), up from 6.6 Korean won a year ago, despite headwinds for the DS Division.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44630345/samsungs-china-chip-pivot-gains-steam-with-54-export-surge-amid-us-market-struggles" rel="noreferrer noopener">Samsung&#8217;s China Chip Pivot Gains Steam With 54% Export Surge Amid US Market Struggles</a>
The DS Division (encompassing Memory and S.LSI / Foundry) posted revenue of 25.1 trillion Korean won (versus 23.1 trillion Korean won Y/Y).
The division reported 1.1 trillion Korean won in operating profit (versus 1.9 trillion Korean won Y/Y) due to the erosion of average selling price (ASP) and a decrease in HBM sales due to export controls on AI chips and deferred demand in anticipation of upcoming enhanced HBM3E products.
Samsung Display Corp Division (SDC) posted 5.9 trillion Korean won in revenue (versus 5.4 trillion Korean won Y/Y) and 0.5 trillion Korean won in operating profit (versus 0.3 trillion Korean won Y/Y).
The Mobile eXperience (MX) and Networks businesses posted 37.0 trillion Korean won in revenue (versus 33.5 Korean won Y/Y). The division reported 4.3 trillion Korean won in operating profit (versus 3.5 trillion Korean won Y/Y).
The quarterly capex was 12.13 trillion Korean won, down from 13.42 trillion Korean won a year ago.
Samsung&#8217;s flagship products, including semiconductors, smartphones, and tablets, are now exempt from reciprocal tariffs. Still, President Donald Trump has&nbsp;indicated&nbsp;that a tariff on the electronics supply chain, including chips, is in the works, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-30/samsung-s-chips-business-beats-estimates-after-stockpiling-push?sref=TBDibEcD" rel="noreferrer noopener">reported</a> Wednesday.
Seoul and Washington agreed to pursue a comprehensive package agreement by July 8, when the 90-day tariff pause will end.
Samsung has struggled for months to secure&nbsp;Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) final nod for its most advanced HBM products, making it challenging to compete with&nbsp;Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).
Samsung is in talks to supply customized sixth-generation high-bandwidth memory, or HBM4, chips to major AI chipmakers, including Nvidia, Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, the Korea Economic Daily <a target="_blank" href="https://www.kedglobal.com/korean-chipmakers/newsView/ked202504300004" rel="noreferrer noopener">reported</a> Wednesday.
Outlook: In the second quarter, the Memory Business anticipates robust demand for AI servers and a ramp-up of the enhanced HBM3E 12H.
AI-related demand is expected to remain high in the second half, in conjunction with the launch of new GPUs.
In the second quarter, the System LSI Business will maintain steady revenue by gaining SoC adoption by a major customer for new flagship models and capitalizing on the growing adoption of 200-megapixel sensors.
In the second half, the System LSI Business will expand its flagship SoC supply and develop its automotive sensor portfolio.
In the second quarter, the Foundry Business will stabilize its 2nm process production and drive earnings improvement by actively addressing strong mobile and automotive demand in the United States. Looking ahead to the second half, the Foundry Business aims to start 2nm mass production, secure major 2nm orders, and strengthen its specialty process portfolio on mature nodes.
In the second quarter, the mobile display business maintained a conservative outlook on earnings while pursuing a stable supply of new products such as foldables.
In the second half, SDC aims to grow mobile display business sales through differentiated technologies and products.
In the second quarter, MX Business plans to sustain flagship-centric sales amid weak seasonality by successfully launching the Galaxy S25 Edge. It will also expand its AI smartphone lineup by introducing &#8220;Awesome Intelligence&#8221; to the Galaxy A series.
In the second half, the MX Business will strengthen its foldable lineup by offering a differentiated AI user experience. In addition, the Business will launch new ecosystem products with enhanced AI and health capabilities and explore new product segments such as XR.
In the second quarter, Visual Display and Digital Appliances intends to expand TV sales with its 2025 AI TV lineup and the integration of advanced AI functions.
In the second half, the Business will focus on capturing peak season demand through strategic collaboration with distributors based on an enhanced AI TV lineup.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/media/25/03/44140452/gm-stellantis-supplier-samsung-sdi-weighs-new-us-battery-plant-amid-trumps-ev-policy-shift" target="_blank" rel="noreferrer noopener">GM, Stellantis Supplier Samsung SDI Weighs New US Battery Plant Amid Trump&#8217;s EV Policy Shift</a></li>
</ul>

Asia

Earnings

Guidance

Emerging Markets

Tech

Media

AVGO

GOOG

GOOGL

NVDA

SSNLF

Samsung Galaxy Sales Soar But Foundry Segment Lags As Trump Tariffs Loom

Barclays analyst George Wang maintains Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Equal-Weight and lowers the price target from $59 to $34.

SMCI

Barclays Maintains Equal-Weight on Super Micro Computer, Lowers Price Target to $34

Barclays analyst Jeffrey Bernstein maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Overweight and lowers the price target from $106 to $98.

SBUX

Barclays Maintains Overweight on Starbucks, Lowers Price Target to $98

Barclays analyst Kannan Venkateshwar maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Overweight and lowers the price target from $710 to $650.

SPOT

Barclays Maintains Overweight on Spotify Technology, Lowers Price Target to $650

Barclays analyst Terry Ma maintains SoFi Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) with a Equal-Weight and raises the price target from $11 to $12.

SOFI

Barclays Maintains Equal-Weight on SoFi Technologies, Raises Price Target to $12

Barclays analyst Tom O'Malley maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Equal-Weight and raises the price target from $80 to $90.

Barclays Maintains Equal-Weight on Seagate Tech Hldgs, Raises Price Target to $90

Goldman Sachs Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) has outperformed the market over the past 5 years by 11.01% on an annualized basis producing an average annual return of 25.16%. Currently, Goldman Sachs Group has a market capitalization of $170.57 billion. 
Buying $100 In GS: If an investor had bought $100 of GS stock 5 years ago, it would be worth $311.05 today based on a price of $546.64 for GS at the time of writing.
<h3>Goldman Sachs Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746052210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Press Releases

Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

Comments

Hoth Therapeutics

Hoth Therapeutics (HOTH) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル